Summit names Kane as CEO | Behavioral Healthcare Executive Skip to content Skip to navigation

Summit names Kane as CEO

May 19, 2015
by Julie Miller, Editor in Chief
| Reprints

Summit Behavioral Health recently announced that Jim Kane will serve as the organization’s new CEO.  Kane has over 38 years of addiction, mental health and healthcare administrative experience.

Previously, while COO at Gosnold on Cape Cod, he oversaw four inpatient treatment programs, seven outpatient centers, ambulatory medication assisted treatment, onsite school behavioral health programming and physician office based counseling services.

Also, he worked as director with Hazelden Foundation for over 12 years, helping to develop the NFL Players Assistance Program, conducting national EAP training, as well as consultation to the NCAA, and helping to establish the first UK/European Addiction Symposium. As co-founder of Cornerstone Health management, Kane helped develop and manage over 65 Primary Care Hospital based mental health programs in 23 states.  

”I am honored to serve as the new CEO of Summit Behavioral Health, especially during a time of extreme growth within the company,” said Kane, in a statement.  “With Summit’s talented team of professionals, I look forward to further enhancing the brand and taking the company to the next level to bring high quality patient and family focused treatment for those struggling with addiction and co-occurring disorders.”  

In January, Summit Behavioral Health (locations in Doylestown. Pa., Princeton Junction, N.J. and a residential detox in Union, N.J.) merged with Treatment Dynamics, acquiring its facilities in Florham Park and Newton, NJ. Summit Behavioral Health offers residential, partial hospitalization and outpatient addiction treatment programs in New Jersey and Pennsylvania, organized into different phases and levels of care.

These include motivational, cognitive-behavioral, relapse prevention, 12-step facilitation, and emotion-focused therapy techniques. A unique aspect of Summit’s treatment is that it addresses “self-medication” behavior and chronic relapse.